Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) aims to cure patients without inducing severe graft-versus-host disease (GVHD) or relapse. In prospective studies of mostly pediatric patients with haploidentical donors, ex vivo αβTCR/CD19 depletion has shown to have low incidences of GVHD, but data for adults with matched related (MRD) or unrelated donors (MUD) remain limited. We analyzed the outcomes of recipients who received a myeloablative regimen plus ATG, followed by an αβTCR/CD19-depleted allograft (cohort D+ATG (n = 122)), and compared outcomes to T cell-replete cohorts (cohort R (N = 60)); without ATG; R+ATG = with ATG (N = 129) in a single-center retrospective analysis. In D+ATG, the incidence of aGVHD grade III–IV was 7%, compared to 13% in R and 16% in R+ATG (p = 0.09). Extensive cGVHD was reduced from 23% in R and 10% in R+ATG to 2% in D+ATG (p < 0.001). The reduced incidence of cGVHD led to a superior GVHD-relapse-free survival (GRFS) of 56.7% in D+ATG versus 36.7% in R and 42.8% in R+ATG (p = 0.03) at 2 years. In conclusion, the combination of myeloablative conditioning, ATG, and ex vivo αβTCR/CD19 depletion appears to be a promising approach to enhance GRFS in adult patients up to 75 years of age undergoing allo-HSCT.
This is a preview of subscription content, access via your institution
Access options
Access through your institution
Change institution
Buy or subscribe
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Learn more
Buy this article
Purchase on SpringerLink
Instant access to full article PDF
Buy now
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Log in
Learn about institutional subscriptions
Read our FAQs
Contact customer support
Fig. 1: Cumulative incidence of aGvHD and cGvHD.
Fig. 2: Relapse and NRM by ex vivo αβTCR/CD19 depletion and conditioning with ATG.
Fig. 3: OS, EFS, and GRFS by ex vivo αβTCR/CD19 depletion and conditioning with ATG.
Data availability
The data that support the findings of this study are available from EBMT the registry, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are, however, available from the authors upon reasonable request and with permission of the corresponding author.
References
Korngold R, Sprent J. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J Exp Med. 1978;148:1687–98.
ArticlePubMedGoogle Scholar
Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol. 2007;7:340–52.
ArticlePubMedGoogle Scholar
Penack O, Marchetti M, Aljurf M, Arat M, Bonifazi F, Duarte RF, et al. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2024;2:e147-e159.
Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10:855–64.
ArticlePubMedGoogle Scholar
Mohty M, Labopin M, Balere ML, Socie G, Milpied N, Tabrizi R, et al. Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Leukemia. 2010;24:1867–74.
ArticlePubMedGoogle Scholar
Pidala J, Tomblyn M, Nishihori T, Ayala E, Field T, Fernandez H, et al. ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17:1237–44.
ArticlePubMedPubMed CentralGoogle Scholar
Socie G, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR, et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood. 2011;117:6375–82.
ArticlePubMedGoogle Scholar
Bonifazi F, Rubio MT, Bacigalupo A, Boelens JJ, Finke J, Greinix H, et al. Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel. Bone Marrow Transplant. 2020;55:1093–102.
ArticlePubMedPubMed CentralGoogle Scholar
Penack O, Abouqateb M, Peczynski C, Boreland W, Kroger N, Stelljes M, et al. ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation? Leukemia. 2024;38:1156–63.
ArticlePubMedPubMed CentralGoogle Scholar
Berger M, Lanino E, Cesaro S, Zecca M, Vassallo E, Faraci M, et al. Feasibility and outcome of haploidentical hematopoietic stem cell transplantation with post-transplant high-dose cyclophosphamide for children and adolescents with hematologic malignancies: an AIEOP-GITMO Retrospective Multicenter Study. Biol Blood Marrow Transplant. 2016;22:902–9.
ArticlePubMedGoogle Scholar
Mussetti A, Greco R, Peccatori J, Corradini P. Post-transplant cyclophosphamide, a promising anti-graft versus host disease prophylaxis: where do we stand? Expert Rev Hematol. 2017;10:479–92.
ArticlePubMedGoogle Scholar
Uygun V, Karasu G, Daloglu H, Ozturkmen S, Caki Kilic S, Hazar V, et al. Haploidentical hematopoietic stem cell transplantation with post-transplant high-dose cyclophosphamide in high-risk children: a single-center study. Pediatr Transplant. 2019;23:e13546.
ArticlePubMedGoogle Scholar
Sharma A, Rastogi N, Chatterjee G, Kapoor R, Nivargi S, Yadav SP. Haploidentical stem cell transplantation with post-transplant cyclophosphamide for pediatric acute leukemia is safe and effective. J Pediatr Hematol Oncol. 2021;43:e1033–e6.
ArticlePubMedGoogle Scholar
Broers AEC, de Jong CN, Bakunina K, Hazenberg MD, van Marwijk Kooy M, de Groot MR, et al. Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial. Blood Adv. 2022;6:3378–85.
ArticlePubMedPubMed CentralGoogle Scholar
Bolanos-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023;388:2338–48.
ArticlePubMedPubMed CentralGoogle Scholar
Finazzi MC, Boschini C, Craddock C, Rambaldi A, Ward J, Malladi RK. Characteristics of graft-versus-host disease occurring after alemtuzumab-containing allogeneic stem cell transplants: incidence, organ involvement, risk factors and survival. Br J Haematol. 2020;188:550–9.
ArticlePubMedGoogle Scholar
de Witte MA, Mooyaart JE, Hoogenboom JD, Chabannon C, Malard F, Ruggeri A, et al. Activity of ex vivo graft and DLI Engineering within the last decade increases, a survey from the EBMT Cellular Therapy & Immunobiology Working Party. Bone Marrow Transplant. 2023;58:719–22.
Nijssen K, Westinga K, Stuut A, Janssen A, van Rhenen A, van der Wagen L, et al. Graft engineering: how long can you wait, how low can you go, and pandemic readiness. Bone Marrow Transplant. 2023;58:820–2.
ArticlePubMedGoogle Scholar
Bertaina A, Romano M, Rutella S, Palumbo G, Pagliara D, Ceccarelli S, et al. HLA haploidentical stem cell transplantation after removal of αβ+ T lymphocytes and B lymphocytes is an effective treatment for children with life-threatening, non-malignant disorders. Blood. 2012;120:2018.
ArticleGoogle Scholar
Locatelli F, Merli P, Pagliara D, Li Pira G, Falco M, Pende D, et al. Outcome of children with acute leukemia given HLA-haploidentical HSCT after alphabeta T-cell and B-cell depletion. Blood. 2017;130:677–85.
ArticlePubMedGoogle Scholar
Bethge WA, Eyrich M, Mielke S, Meisel R, Niederwieser D, Schlegel PG, et al. Results of a multicenter phase I/II trial of TCRalphabeta and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients. Bone Marrow Transplant. 2022;57:423–30.
ArticlePubMedGoogle Scholar
Leahy AB, Li Y, Talano JA, Elgarten CW, Seif AE, Wang Y, et al. Unrelated donor alpha/beta T cell- and B cell-depleted HSCT for the treatment of pediatric acute leukemia. Blood Adv. 2022;6:1175–85.
ArticlePubMedPubMed CentralGoogle Scholar
de Witte MA, Janssen A, Nijssen K, Karaiskaki F, Swanenberg L, van Rhenen A, et al. alphabeta T-cell graft depletion for allogeneic HSCT in adults with hematological malignancies. Blood Adv. 2021;5:240–9.
ArticlePubMedPubMed CentralGoogle Scholar
Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23:5675–87.
ArticlePubMedGoogle Scholar
Chaleff S, Otto M, Barfield RC, Leimig T, Iyengar R, Martin J, et al. A large-scale method for the selective depletion of alphabeta T lymphocytes from PBSC for allogeneic transplantation. Cytotherapy. 2007;9:746–54.
ArticlePubMedGoogle Scholar
Li Pira G, Malaspina D, Girolami E, Biagini S, Cicchetti E, Conflitti G, et al. Selective depletion of alphabeta T cells and B cells for human leukocyte antigen-haploidentical hematopoietic stem cell transplantation. A three-year follow-up of procedure efficiency. Biol Blood Marrow Transplant. 2016;22:2056–64.
ArticlePubMedGoogle Scholar
Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628–33.
ArticlePubMedPubMed CentralGoogle Scholar
Carreras E, Dufour C, Mohty M, Kroger N, editors. The EBMT handbook: hematopoietic stem cell transplantation and cellular therapies. 7th ed. Cham: Springer; 2019.
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone marrow Transplant. 1995;15:825–8.
PubMedGoogle Scholar
Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9:215–33.
ArticlePubMedGoogle Scholar
Teira P, Battiwalla M, Ramanathan M, Barrett AJ, Ahn KW, Chen M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016;127:2427–38.
ArticlePubMedPubMed CentralGoogle Scholar
Fujimoto A, Suzuki R. Epstein-Barr virus-associated post-transplant lymphoproliferative disorders after hematopoietic stem cell transplantation: pathogenesis, risk factors and clinical outcomes. Cancers. 2020;12:328–51.
Kroger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med. 2016;374:43–53.
ArticlePubMedGoogle Scholar
de Witte M, Daenen LGM, van der Wagen L, van Rhenen A, Raymakers R, Westinga K, et al. Allogeneic stem cell transplantation platforms with ex vivo and in vivo immune manipulations: count and adjust. Hemasphere. 2021;5:e580.
ArticlePubMedPubMed CentralGoogle Scholar
Luznik L, Pasquini MC, Logan B, Soiffer RJ, Wu J, Devine SM, et al. Randomized phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies. J Clin Oncol. 2021;40:356–68.
Lum SH, Albert MH, Gilbert P, Sirait T, Algeri M, Muratori R, et al. Outcomes of HLA-mismatched HSCT with TCRalphabeta/CD19 depletion or post-HSCT cyclophosphamide for inborn errors of immunity. Blood. 2024;144:565–80.
Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377:2433–44.
ArticlePubMedGoogle Scholar
Marzolini MAV, Mehra V, Thomson KJ, Tholouli E, Bloor AJC, Parker A, et al. Letermovir prophylaxis in T-cell-depleted transplants: breakthrough and rebound infections in the postmarketing setting. Blood Adv. 2021;5:4500–3.
ArticlePubMedPubMed CentralGoogle Scholar
Russo D, Schmitt M, Pilorge S, Stelljes M, Kawakita T, Teal VL, et al. Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2024;11:e127–e35.
ArticlePubMedGoogle Scholar
Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, et al. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transplant. 2020;55:1114–25.
ArticlePubMedGoogle Scholar
Pagliuca S, Schmid C, Santoro N, Simonetta F, Battipaglia G, Guillaume T, et al. Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT. Lancet Haematol. 2024;11:e448–58.
ArticlePubMedGoogle Scholar
Download references
Author information
Author notes
These authors contributed equally: A. H. G. Stuut, C. Nijssen.
These authors jointly supervised this work: J. Kuball, M. A. de Witte.
Authors and Affiliations
Center for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
A. H. G. Stuut, J. Drylewicz, J. Kuball & M. A. de Witte
Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
C. Nijssen, L. van der Wagen, A. van Rhenen, L. G. M. Daenen, A. Janssen, F. A. Verheij, I. Brinkman, J. Kuball & M. A. de Witte
Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands
F. M. Verduyn Lunel
Department of Internal Medicine, Antonius Ziekenhuis, Nieuwegein, The Netherlands
H. Koene
Department of Internal Medicine, Meander Medisch Centrum, Amersfoort, The Netherlands
A. Janssen & R. Fijnheer
University Medical Center Utrecht, Utrecht, The Netherlands
H. J. Prins & K. Westinga
Authors
A. H. G. Stuut
View author publications
You can also search for this author in PubMedGoogle Scholar
2. C. Nijssen
View author publications
You can also search for this author in PubMedGoogle Scholar
3. L. van der Wagen
View author publications
You can also search for this author in PubMedGoogle Scholar
4. A. van Rhenen
View author publications
You can also search for this author in PubMedGoogle Scholar
5. L. G. M. Daenen
View author publications
You can also search for this author in PubMedGoogle Scholar
6. A. Janssen
View author publications
You can also search for this author in PubMedGoogle Scholar
7. F. A. Verheij
View author publications
You can also search for this author in PubMedGoogle Scholar
8. I. Brinkman
View author publications
You can also search for this author in PubMedGoogle Scholar
9. F. M. Verduyn Lunel
View author publications
You can also search for this author in PubMedGoogle Scholar
10. H. Koene
View author publications
You can also search for this author in PubMedGoogle Scholar
11. R. Fijnheer
View author publications
You can also search for this author in PubMedGoogle Scholar
12. H. J. Prins
View author publications
You can also search for this author in PubMedGoogle Scholar
13. K. Westinga
View author publications
You can also search for this author in PubMedGoogle Scholar
14. J. Drylewicz
View author publications
You can also search for this author in PubMedGoogle Scholar
15. J. Kuball
View author publications
You can also search for this author in PubMedGoogle Scholar
16. M. A. de Witte
View author publications
You can also search for this author in PubMedGoogle Scholar
Contributions
MdW and JK were responsible for the conception and design of the study. MdW and JK were funded for the study. LvdW, AvR, LvH, AJ, HK, RF, JK, and MdW actively managed the patients. AS, CN, FV, IB, FVL, HK, RF, HJP and KW collected the data. AS, CN, IB, and FV had full access to and verified the underlying data. AS, CN, JD, JK, and MdW contributed to data analysis and interpretation. AS, CN, JD, JK, and MdW wrote the original draft of the manuscript. AS and CN prepared the figures. AS and MdW were responsible for the submission of the manuscript. All authors were responsible for the critical revision of the manuscript and approved the final version of the manuscript.
Corresponding author
Correspondence to M. A. de Witte.
Ethics declarations
Competing interests
JK is the inventor of multiple patents dealing with gdTCRs, ligands, and isolation strategies of engineered immune cells. JK is cofounder and shareholder of Gadeta (www.gadeta.nl). JK received research, advisor, and clinical study support from Miltenyi Biotech. JK received further research support from Novartis and Gadeta.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Supplementary material
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
Reprints and permissions
About this article
Check for updates. Verify currency and authenticity via CrossMark
Cite this article
Stuut, A.H.G., Nijssen, C., van der Wagen, L. et al. Improved GVHD-free and relapse-free survival after ex vivo αβTCR and CD19 depleted allogeneic HSCT compared to T cell replete HSCT. Bone Marrow Transplant (2025). https://doi.org/10.1038/s41409-025-02538-w
Download citation
Received:28 August 2024
Revised:08 January 2025
Accepted:14 February 2025
Published:15 March 2025
DOI:https://doi.org/10.1038/s41409-025-02538-w
Share this article
Anyone you share the following link with will be able to read this content:
Get shareable link
Sorry, a shareable link is not currently available for this article.
Copy to clipboard
Provided by the Springer Nature SharedIt content-sharing initiative